BLAINJECTIONINJECTABLE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PAVBLU (aflibercept-ayyh) by Amgen is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2024.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAVBLU (aflibercept-ayyh) is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF), approved in August 2024 as a biosimilar to Eylea. It treats multiple retinal and systemic cancers by blocking abnormal blood vessel growth that drives vision loss and tumor progression.
Growth
Early-stage biosimilar launch creates demand for commercial and clinical teams to establish market presence and clinical evidence in a large, established ophthalmology and oncology market.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PAVBLU generates significant career demand (1,146 linked jobs) across Amgen, spanning clinical operations, manufacturing scale-up, and commercial forecasting roles. This reflects the breadth of organizational effort required for a biosimilar launch into established markets with complex supply chains and payer negotiations.
Clinical Scientist Director
Worked on PAVBLU at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.